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Scleroderma is a disease characterized by immune activation, vasculopathy, ﬁbroblast stimulation, and connective tissue ﬁbrosis.
End-organ damage occurs due to progressive tissue ﬁbrosis and vasculopathy. Markers of incipient vasculopathy have not been
well studied in scleroderma. However, reduced renal functional reserve and proteinuria are common indicators of progressive
vasculopathy in diabetic and hypertensive vasculopathy. Recent studies suggest a strong association between renal involvement
and outcomes in scleroderma, with a threefold increased risk of mortality from pulmonary hypertension if renal insuﬃciency is
present.Wereviewthetypesofrenalinvolvementseeninsclerodermaandthedatatosupporttheuseofrenalparametersincluding
proteinuria,glomerularﬁltrationrate,andrenalvasculardynamicsmeasuredwithDopplerultrasoundtoidentifysubclinicalrenal
insuﬃciency. Further studies are warranted to investigate the use of renal parameters as prognostic indicators in scleroderma.
1.Introduction
Systemic sclerosis (SSc) is a chronic multisystem disorder
with an annual incidence of 1 to 2 per 100,000 individuals
in the United States. It has a peak age of onset of between
30 and 50 years and a strong female predominance [1]. The
exact pathogenesis of SSc remains elusive but, autoantibody
production, lymphocyte and ﬁbroblast activation, vascular
proliferation, obliterative microvascular disease, and con-
nective tissue ﬁbrosis all likely play a role [2]. In advanced
disease, end-organ damage occurs as a result of progressive
ﬁbrosis and vasculopathy. Often by the time organ injury
is identiﬁed, there is little that can be done to reverse
vasculopathy, and therefore there is a strong impetus in
the scleroderma community to identify potential markers
of incipient vasculopathy before damage becomes clinically
apparent and irreversible.
Numerous other diseases associated with vascular dam-
age, such as diabetes and hypertension, use markers of renal
impairment as preclinical indicators of vasculopathy. In this
paper we review the types of renal involvement reported
in scleroderma and discuss preclinical markers of renal
pathology that might be helpful in identifying scleroderma
patients at risk for progressive vasculopathy.
2. ClinicalSubsets of Scleroderma
Two subsets of scleroderma, with diﬀerent autoantibody
proﬁles and internal organ involvement are recognized [3]:
limited cutaneous scleroderma (lcSSc) in which cutaneous
involvement is limited to the hands, face, feet, and forearms
and diﬀuse cutaneous scleroderma (dcSSc) in which there is
extensive skin involvement extending above the elbows and
knees and involving the trunk. A further group, scleroderma
sine scleroderma (sSSc) in which patients have manifesta-
tions of visceral disease without skin involvement, has an
identicalprognosistolcSScandisincludedinthelcSScgroup
[3–5]. Patients with scleroderma sine scleroderma are often
unaware of the disease until end-organ damage becomes
apparent. These subsets are well described elsewhere.2 International Journal of Rheumatology
Table 1: Reported renal manifestations of scleroderma.
Reported renal manifestations of scleroderma
Scleroderma renal crisis
Normotensive scleroderma renal crisis
Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (MPO-
ANCA) associated glomerulonephritis and vasculitis
Penicillamine-associated renal disease
Antiphospholipid-associated nephropathy
Isolated reduced glomerular ﬁltration rate
Reduced renal functional reserve
Microalbuminuria and proteinuria
Scleroderma-associated vasculopathy manifested by abnormal
renal vascular resistance indices and endothelial markers
Patients with dcSSc develop rapidly progressive skin
involvement with early organ involvement including inter-
stitial lung disease, scleroderma renal crisis, and gastroin-
testinal involvement. One of the predictors of scleroderma
renal crisis is the presence of the RNA polymerase III
antibody (Pol3), and patients with this antibody are at high
risk for early scleroderma renal crisis (SRC). In contrast,
the anticentromere antibody is negatively associated with
scleroderma renal crisis. Patients with limited scleroderma
tend to have more indolent progression of skin disease
but with time develop complications from vascular injury
such as gastric antral vascular ectasia [6] and pulmonary
hypertension.
3. Renal Disease in Scleroderma
Several forms of renal involvement are recognized in
scleroderma. The most dramatic of these is scleroderma
renal crisis which is seen in approximately 10% of the
sclerodermapopulation[7].Autopsystudies,however,reveal
occult renal pathology in 60% to 80% of patients with
systemic sclerosis [8]. Others have found that up to 50%
of asymptomatic patients have clinical markers suggesting
renal disease such as proteinuria, elevation of creatinine, or
hypertension [9]. Renal impairment from chronic renal vas-
culopathy, nephrotoxic medications (including cyclosporine
and D-penicillamine), and glomerulonephritis have all been
reported (Table 1)[ 10, 11].
3.1. Scleroderma Renal Crisis. Scleroderma renal crisis (SRC)
is one of the most well-recognized complications of scle-
roderma. It is manifested by acute onset of moderate-
to-severe hypertension with hyperreninemia, thrombotic
microangiopathy, and progressive renal failure [7]. Biopsy
reveals severe mucinoid hyperplasia and vascular ﬁbrinoid
necrosisoftheinterlobularandarcuatearteriesandarterioles
(Figure 1) with relative sparing of the glomeruli and absence
of inﬂammatory or immune deposits. With advanced renal
crisis secondary ischemic changes in the glomeruli may
occur.
The pathologic ﬁndings seen in SRC suggest that it is
an acute vascular manifestation of the disease. However, the
Figure 1: Hemotaxylin and Eosin stain of renal biopsy from
a patient with scleroderma renal crisis, showing onion skinning
concentric narrowing of arterioles with ischemia of glomeruli with
ﬂattening and degeneration of the tubular cells.
renal vascular lesions may be present in SSc patients with
normal renal function. Presence of these changes correlates
with abnormal plasma rennin levels at baseline and in
response to cold exposure but do not always correlate with
development of SRC [12]. Risk factors for SRC include early
(less than 5 years of disease) diﬀuse scleroderma, rapidly
progressive skin thickening, presence of Pol3 antibody,
and prior exposure to corticosteroids (>15mg prednisone
equivalent in the prior six months) [13]. Renal crisis is
seen in approximately 10–20 percent of patients with dcSSc
and only 1 percent of patients with lcSSc. However, of
patients developing SRC, 78% had dcSSc [14]. Steroids are a
precipitantin60%ofpatientswithSRC[14,15].Angiotensin
converting enzyme inhibitors (ACE inhibitors) have been
pivotal in the treatment of SRC, and since their introduction,
mortality and renal morbidity has declined dramatically
[16].
3.2. Normotensive Scleroderma Renal Crisis. An u m b e ro f
cases of acute, rapidly progressive renal failure with con-
comitant thrombotic microangiopathy but no malignant
hypertension have been described, and this complication
is termed “normotensive scleroderma renal crisis” [17, 18].
This manifestation is rare, accounting for only 11% of scle-
roderma renal crisis cases, and is associated with increased
frequency of pulmonary hemorrhage and increased mor-
tality. Anecdotal reports suggest that this presentation of
renal crisis may be more common in patients receiving ACE
inhibitors, but the mechanism by which this occurs is not
well understood.
3.3. Coexistent MPO-ANCA-Associated Glomerulonephritis
andScleroderma. Severalauthorshavereportedmyeloperox-
idase antineutrophil cytoplasmic antibody- (MPO-ANCA-)
associated glomerulonephritis resulting in renal failure in
scleroderma [10, 19, 20]. In contrast to classical scleroderma
renal crisis, these patients tend to have established lcSSc,
and the process has a subacute presentation with progressive
renal failure, mild hypertension, and proteinuria. ThisInternational Journal of Rheumatology 3
diagnosis should be considered in any scleroderma patient
with positive MPO antibodies and renal failure. It has been
postulated that scleroderma vasculopathy exacerbates the
interaction of ANCA with endothelium near the vascular
pole and neutrophil activation in the glomerulus. This
manifestation does not respond to ACE inhibitors but is
steroid responsive. However, biopsy is often required to
exclude scleroderma renal crisis.
3.4. Penicillamine-Induced Renal Injury in Scleroderma. D-
Penicillamine is rarely used now but historically has been
used in treatment of Wilson’s disease, cystinuria, rheumatoid
arthritis, primary biliary cirrhosis, lead poisoning, and
systemic sclerosis. Up to 20% of patients treated with D-
penicillamine develop membranous glomerulopathy with
proteinuria which resolves with cessation of the medica-
tion. Drug-induced lupus syndrome, diﬀuse proliferative
cresentic glomerulonephritis, and cases of pulmonary renal
syndrome mimicking Goodpasture’s Syndrome have also
been reported [21]. Typically these manifestations improve
with withdrawal of the D-penicillamine, but in severe cases
steroids,plasmapheresis,and immunosuppression havebeen
required. Based on cases reported in the literature, this
complication has a roughly 40% mortality.
3.5.Antiphospholipid-AssociatedNephropathyinScleroderma.
Unlike in other autoimmune diseases, the frequency of
antiphospholipid antibodies in scleroderma is reported to
be no greater than that seen in the general population
ranging from 3.3% to 12% [22–24]. Based on a single aPL
antibody measurement of anticardiolipin (ACL) or Beta-
2 glycoprotein I (B2GPI) antibody of IgM or IGG class,
Wielosz et al. found that 56% of SSc patients had positive
aPLantibodies[25].Theycorrelatedantibodypositivitywith
renalfunctionparametersandfoundthatalthoughtherewas
no diﬀerence in serum creatinine between the aPL positive
group and the aPL negative group, IgG ACL was associated
with elevation of serum cystatin C (a marker of reduced
glomerular ﬁltration rate) and negatively associated with
creatinine clearance. Furthermore, proteinuria (>0.5g/24
hours) was found in 21% of the APL positive patients but
only in 9% of the APL negative patients. aPL positivity was
also associated with development of SRC, which occurred
in 21% of the patients with positive aPL and none of the
patients with negative aPL. Larger studies are needed to
clarify these ﬁndings, but this suggests that aPL antibodies
may play a role in renal injury in scleroderma.
3.6. Isolated Reduced Glomerular Filtration Rate in Sclero-
derma. Impairment of renal function can be present in SSc
despitenormalserumcreatinine[26].Theprincipaldetermi-
nants of creatinine are muscle mass and glomerular ﬁltration
rate (GFR), and it is well recognized that serum creatinine
maynotbeelevateduntiltheGFRislessthan50%ofnormal.
Kingdon et al. evaluated patients followed in the Royal Free
Hospital Scleroderma Clinic and found reduced GFR as
measured by chromium-51-ethylenediaminetetraacetic acid
(51Cr-EDTA) clearance in 95% of patients with serum
creatinine within the normal range and all the patients
with elevated creatinine. These patients also had abnormal
calculated GFR. In patients with serum creatinine below the
normal range (<60μmol/L) the measured GFR was normal.
The highest correlation between measured and calculated
GFR was seen when the Modiﬁcation of Diet in Renal
Disease (MDRD) formula was used. This group advocates
using MDRD to calculate GFR at baseline and followup
visits.
More recently Scheja et al. have tried to investigate the
occurrence of reduced GFR in a large cohort of 461 Swedish
SSc patients followed over 10 years [27]. They measured
GFR using either chromium-51-ethylenediaminetetraacetic
acid (51Cr-EDTA) or by iohexol clearance. Patients with
a history of SRC or who developed SRC during follow-
up were excluded from analysis. Median follow up was
7.7 years (range 0.5–54 years). Decreased GFR was found
in 11% of lcSSc and 8.6% of dcSSc, which accounts for
approximately 10% of the total initial cohort. This is lower
than reported in the Royal Free study but may simply reﬂect
diﬀering inclusion criteria. The Swedish study included
461 consecutive SSc patients; in contrast the Royal Free
study included only 26 patients who were selected based on
availability of measured and calculated GFR results on two
occasions, an inclusion criteria which is likely to bias the
resultstowardsoverrepresentationofpatientswithabnormal
GFR. Of the patients with GFR <70% predicted in the
Swedish cohort, 60% had hypertension, 52% had cardiac
involvement,and19%hadothernephropathiesidentiﬁedon
biopsy. Follow up data beyond 4 years was only available in
15 patients, but the majority (73%) had no progression of
renal disease in that time.
Steen et al. examined records of 675 patients with dcSSc,
and after excluding the 19.5% who developed SRC, they
found 32% with abnormal renal function or proteinuria
[28]. Most patients had proteinuria from penicillamine or
other medical comorbidities. Only 2% had no explanation
for elevated creatinine level. Over a mean follow-up of 10
years,noneofthesepatientsdevelopedrenalfailurerequiring
dialysis, suggesting that although mild renal insuﬃciency
is common in SSc, it often follows a more benign clinical
course.
A smaller study from Cairo has evaluated 31 SSc patients
and compared them to 31 healthy controls [29]. GFR was
measured using technetium 99m DTPA (Tc99mDTPA) and
calculated using MDRD and Cockcroft-Gault formulae. All
patients had normal serum creatinine and normal renal
ultrasound. Measured GFR was normal (>89ml/min) in
45.1% but reduced in 54.9% as follows: Stage II CKD 60–
89ml/min 32.3%, Stage III (30–59ml/min) in 22.6%. Renal
impairment correlated to pulmonary vascular involvement
but did not correlate with age, disease duration, lung ﬁbro-
sis, gastrointestinal involvement, cardiac involvement, skin
score, muscle involvement, antibody proﬁle, or treatment
exposures.
The association between renal dysfunction and pul-
monary hypertension in SSc is increasingly becoming
recognized. Campo et al. recently evaluated 76 consec-
utive SSc patients with pulmonary arterial hypertension
(PAH) and found that 45.6% had renal dysfunction (eGFR
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6.5% having had a prior episode of renal crisis [30].
Furthermore, eGFR was a strong predictor of survival in this
cohort, with eGFR <60mL/min/1.73m2 associated with a
3-fold risk of mortality. This strong association may be a
reﬂection of pulmonary hypertension and right heart failure
contributing to renal dysfunction through ﬂuid retention
and neuroendocrine activation. However, further studies are
warranted to evaluate the role of renal dysfunction in SSc-
associated pulmonary hypertension.
3.7. Reduced Renal Functional Reserve in Scleroderma. Renal
functional reserve is a measure of the kidney’s ability to
increase GFR after stimulation with oral protein or IV amino
acid load. Livi et al. studied renal functional reserve in
21 SSc patients (16 with lcSSc and 5 with dcSSc) with
normal renal function and compared them to 10 control
patients [31]. Eﬀective renal plasma ﬂow (ERPF) using
para-aminohippurate clearance and calculated total renal
vascular resistance (TRVR) were measured before and after
an intravenous amino acid load. Creatinine clearance was
similar at baseline in the two groups. However, the ERPF
response was signiﬁcantly lower, and TRVR was higher in
patients than controls. In normal subjects, GFR should rise
by 10% in response to stimulation, but only 28.6% of the
SSc patients showed this response. Blunted renal functional
reserve was seen in 80% of patients with dcSSc and 68.75%
of patients with lcSSc. Additional studies are needed to
establish if lack of renal functional reserve in SSc is a
predictor of developing clinically evident renal involvement
or vasculopathy in other organs.
3.8. Proteinuria in Scleroderma. Albuminuria is a useful
marker of vasculopathy and is known to be an indepen-
dent predictor of cardiovascular morbidity and mortality
in patients with and without other vasculopathic diseases
such as diabetes and hypertension [32–36]. Seiberlich et
al. analyzed urine albumin, urine total protein, and urine
electrophoresis to assess protein excretion in 80 SSc patients
and 18 healthy age- and gender-matched controls [37].
All subjects had a normal GFR. Increased total protein
excretionwasseenin17.5%ofSScpatients, andalbuminuria
was identiﬁed in 25% (22.5% microalbuminuria and 2.5%
macroalbuminuria). Albuminuria correlated with disease
duration >4 years and elevation of systolic blood pressure,
suggesting it may be reﬂective of chronic vascular injury.
Dawnay et al. evaluated urine albumin in a cohort of sclero-
derma patients and found prevalence of microalbuminuria
of 17.9% but this could not be correlated with clinical
outcome due to the small sample size [38]. Larger studies are
needed to evaluate the role of albuminuria as a predictor of
morbidity, mortality, and outcome in scleroderma.
Urine electrophoresis has not been widely studied in the
scleroderma population. In general, urine electrophoresis
results are categorized into three patterns depending on the
molecular weight of the protein detected. Low molecular
weight proteinuria (LMWP) is usually due to diminished
tubular resorptive capacity for example from interstitial
nephritis and nephrotoxicity. In the Seiberlich study, LMWP
was seen at a similar frequency in the SSc group as controls
[37]. Intermediate weight proteinuria (IMWP) is a sensitive
predictor of increased glomerular permeability and has
been described in other forms of vasculopathy including
diabetes and hypertension [39]. Urine electrophoresis in the
Seiberlich study revealed IMWP in 31.3% of SSc patients,
but none of the control subjects. IMWP was seen in 50%
of patients with dcSSc compared to only 20% of lcSSc and
correlated to the presence of gastrointestinal involvement.
Francois et al. have also reported an association of glomeru-
lar proteinuria with scleroderma but did not correlate this to
clinical parameters [40]. High molecular weight proteinuria
(HMWP) is generally a reﬂection of glomerulonephritis and
was not seen in any of the SSc patients or controls in the
Seiberlich study.
Further studies are warranted to investigate the role of
proteinuria and albuminuria detection in the scleroderma
population. In diabetic vasculopathy it is recommended that
initiationofangiotensinconvertingenzyme(ACE)inhibitors
when microalbuminuria is detected is eﬀective at delaying
progressiontoadvanceddiseaseandimprovescardiovascular
outcomes [41]. While ACE inhibitors are known to exhibit
antiﬁbrotic eﬀects [42] in addition to lowering systemic
blood pressure, the use of prophylactic ACE inhibitors is
generally not recommended in SSc. Use of prophylactic ACE
inhibitors in SSc does not protect against SRC [15, 43], and
theirusepriortodevelopmentofSRCmaybeassociatedwith
w o r s eo u t c o m e s[ 14, 44] although this data was not adjusted
for confounders, and the reported association did not reach
statistical signiﬁcance.
3.9. Renal Vascular Resistance Indices in Scleroderma. With
the advent of new imaging techniques, several groups have
investigated the use of non-invasive testing such as renal
Doppler ultrasound to evaluate intrarenal vasculature in
scleroderma patients.
In patients with lupus nephritis the renal vascular
resistance index (RI) is a predictor of poor outcome,
correlating with creatinine level and chronicity score on
biopsy[45].RImeasuresintrarenalelasticityandcompliance
and tends to be more sensitive to vascular and interstitial
nephropathies because glomeruli are only responsible for
10% of the intraparenchymal ﬂow resistances. Release of
vasoconstrictive substances results in renal remodeling and
elevation of RI as renal vascular disease progresses. In hyper-
tension, both RI and albuminuria improve with angiotensin
receptor blocking (ARB) agents [46], suggesting that RI
may be measuring a potentially reversible component of
vasculopathic damage.
Investigating SSc patients without clinical evidence of
renal damage, Rivolta et al. measured RI on the main,
interlobar, and cortical vessels in 25 SSc subjects and 25
normal volunteers. SSc patients had signiﬁcantly elevated
RI at every sampling site [47]. RI values correlated with
disease duration but not creatinine clearance. These ﬁndings
have since been replicated in a study evaluating 9 SSc
patients with renal impairment, 13 SSc patients with normal
renal function, and 20 age-matched controls. There was no
signiﬁcant diﬀerence in peak systolic ﬂow velocities in any
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groups. However, the mean end diastolic ﬂow velocity
(EDFV) in the interlobular artery (ILA) was lower in the
SSc patients with renal disease compared to the SSc patients
without renal involvement. SSc patients with renal disease
hadhighersystolictodiastolicﬂowvelocities(S/Dratio).The
mean RI and pulsatile index (PI) were higher in SSc patients
with renal disease than those without. RI, PI, and S/D ratios
correlated with disease duration but were over and above
thosethatmighthavebeenexpectedwithage.Furtherstudies
are warranted to evaluate the use of Doppler ultrasound in
predicting renal complications in scleroderma.
3.10. Renal Vascular Responsiveness to Iloprost in Scleroderma.
Further understanding of the mechanisms of vascular
involvement in SSc is obtained by evaluating the response of
renal and other vascular beds to vasodilating agents.
In normal tissue, prostacyclin is released locally from
platelets and vascular endothelium and inhibits production
of endothelin, a potent vasoconstrictor. SSc patients have
elevated levels of endothelin I and are known to be prone
to toxicity from cyclosporine, an agent that causes vasocon-
striction and elevation of endothelin I. Furthermore, there is
some evidence that endothelin I may play a role in SRC [48].
Iloprost is a stable prostacyclin analogue with vasodila-
tory and platelet aggregating eﬀects. It is used in Raynaud’s
syndrome and is eﬀective in healing cutaneous scleroderma
lesions. It has long lasting eﬀects on peripheral blood ﬂow
and improves pulmonary artery resistance in PHT. In the
kidney it increases renal plasma ﬂow by dilating aﬀerent
and eﬀerent arterioles, without changing GFR, and some
centers recommend including intravenous iloprost during
the hypertensive phase of SRC [44].
Scorza et al. investigated the eﬀect of iloprost on RI in
the renal vessels and compared it to the calcium channel
antagonist nifedipine [49]. They found that acute iloprost
infusion resulted in signiﬁcant drop of RI in the interlobar
and cortical vessels without causing systemic hypotension.
U s eo fi l o p r o s tf o r8h o u r sp e rd a yf o r5d a y sh a dl o n g -
lasting eﬀect on reducing the RI values in the interlobular
and cortical arteries at 2 weeks. In contrast, 6 months of
nifedipine treatment did not alter the RI of the renal vessels.
Long-term renal outcomes in response to iloprost ther-
apy remain to be elucidated. Air` o et al. evaluated the use
of cyclic iloprost in a cohort of SSc patients with severe
digital ulcers and Raynaud’s and compared pulmonary and
renal outcomes over 4 years with age, sex- and disease-
matched controls [50]. There was no detectable diﬀerence in
pulmonary, renal, or long-term outcomes in this study but
selectionbiasandotherconfoundingmayhaveaﬀectedthese
results.
3.11. N-Acetylcysteine Infusion in Early Scleroderma. Renal
hemodynamics in SSc patients have also been studied
in response to N-Acetylcysteine (NAC) [51]. NAC is a
sulfhydryl precursor of glutathione with potent antioxidant
and cellular detoxifying actions. Via vasodilation and actions
on oxygen free radical scavenging, NAC has been show
to improve myocardial function after myocardial infarction
[52]. In the kidney, NAC has been shown to enhance
renalglutathione,amelioraterenalfunction,decreasearterial
pressure and renal injury in salt sensitive hypertension,
and improve endothelial dysfunction in dialysis patients by
preventing ﬂow-mediated dilatation [53, 54]. In radiocon-
trast exposure, it has an antioxidant function and causes
vasodilatation and enhanced renal medullary ﬂow [55].
In an open-label study [51], 40 SSc patients with
either early or late capillaroscopic changes received NAC
intravenously for 5 hours at 0.015g/Kg/h, and renal hemo-
dynamics were assessed using RI. In patients with early
capillaroscopic changes, NAC reduced RI. In contrast, in the
group with late capillaroscopic pattern, RI was increased.
Based on these ﬁndings, it appears that NAC results in
renal arterial vasodilation only if given early in the course
of disease, prior to irreversible arteriopathy. Patients in this
study with late capillaroscopic changes all had low diﬀusion
capacity for carbon monoxide (DLCO), suggesting that they
had a component of pulmonary vascular involvement. It
seems that as vasculopathy becomes more extensive, NAC
may have a detrimental eﬀect, and the implications of this
for the use of NAC clinically are unclear.
3.12. Vascular Endothelial Markers in Scleroderma Renal
Disease. Cytokine activation of endothelial cells in states of
inﬂammation induces expression of adhesion molecules that
allow recruitment of leukocytes to the sites of inﬂammation
[56, 57]. Activated, endothelial cells shed soluble forms of
these adhesion molecules including intracellular adhesion
molecule-1 (ICAM1), vascular cell adhesion molecule-1
(VCAM1), and E-selectin (E-selectin), and these molecules
can be detected in the serum. It is thought that E-selectin
has the greatest speciﬁcity for cytokine-activated cells. Prior
studies have shown elevation of these molecules in diseases
with endothelial injury including SLE, vasculitis, and sepsis
[58, 59].
Stratton et al. evaluated levels of E-selectin, ICAM-1,
and VCAM-1 in serum of SSc patients with and without
SRCandSSc-associatedpulmonaryhypertension(PHT)and
compared them to control patients with primary Raynaud’s
[60]. They found that E-selectin was elevated approximately
25% above normal in patients with lcSSc without SRC or
PHT. In contrast, E-selectin levels were normal in patients
with lcSSc and PHT, suggesting that the vascular lesions
of PHT were not associated with activated endothelial cell
phenotype. Although SRC is rare in lcSSc, E-selectin levels
were two times normal in the lcSSc-SRC group, suggesting
that there are diﬀerent pathogenic mechanisms of vascular
injury in SRC and PHT. Notably, all patients with dcSSc and
PHT (all of whom had concomitant interstitial disease) did
show elevation of E-selectin, suggesting that inﬂammatory
lung disease leads to activation of endothelial cells in the
pulmonary microcirculation with increased expression and
shedding of E-selectin.
Serum VCAM-1 levels were elevated in both lcSSc and
dcSScpatientswithSRC.Theywerealsoincreasedinpatients
with lcSSc without SRC or PHT, suggesting they may be a
reﬂection of the chronic vascular injury in this subgroup
of patients. Soluble ICAM-1 levels were raised in all groups
with the highest levels being seen in dcSSc with PHT.6 International Journal of Rheumatology
Analysis of serial measurements did not show consistent
trends or progressive increase in endothelial markers over
time. Likewise, in patients with SRC, endothelial markers
were not consistently elevated at the time of SRC.
4. Conclusions
Mild chronic renal insuﬃciency in scleroderma is prob-
ably under recognized and may be a manifestation of
vasculopathy. Recent studies suggest a strong association
between renal involvement and outcomes in scleroderma,
with a threefold increased risk of mortality from pulmonary
hypertension if renal insuﬃciency is present. Current data
suggests that manifestations of renal insuﬃciency including
proteinuria and altered renal vascular dynamics as measured
with Doppler ultrasound may help identify early signs of
renal involvement, and this may be a surrogate marker of
vasculopathy. Further studies are warranted to investigate
renal markers as prognostic indicators and targets for disease
modifying therapy in scleroderma.
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